Abstract

The present invention refers to an in vitro method for the prognosis of patients suffering from HER2+ breast cancer, for the prediction of response to anti-HER2 therapies and/or for predicting survival benefit from anti-HER2 therapies.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes

Abstract

The present invention provides Interleukin-13 Receptor Subunit Alpha-2 (IL13Rα2) targeting moieties, and CAR comprising them, which may be transduced or transformed into T cells. The resultant CARTs are suitable for the treatment and prevention of IL13Rα2-positive cancers, such as glioblastoma or diffuse intrinsic pontine glioma.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells

Abstract

The present invention provides a fusion protein suitable to reduce graft-versus-host and host-versus-graft reactions in allogenic transplants. Said fusion protein comprises an anti-CD3 targeting moiety and a human cytomegalovirus US6 protein.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 40/30 - Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
• A61K 40/31 - Chimeric antigen receptors [CAR]

Abstract

The present invention relates to T cells expressing bispecific antibodies for BCMA and CD3 and uses thereof in the treatment of cancer, in particular cancers which overexpress BCMA antigen.

IPC Classes  ?

• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/33 - AntibodiesT-cell engagers
• A61K 40/42 - Cancer antigens
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

It relates to statins or their pharmaceutically acceptable salts for use in the prevention and/or treatment of splanchnic vascular dysfunctions in a patient which is a mammal wherein the prevention and/or treatment comprises inhibiting and/or reverting endothelial-to-mesenchymal transition of endothelial cells.

IPC Classes  ?

• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors

Abstract

The present invention relates to a CD7 targeting moiety, wherein the CD7 targeting moiety is an antibody, F(ab')2, Fab, scFab or scFv. The present invention further provides CD7 retention domains, CARs, nucleic acid, cells, pharmaceutical compositions and kits comprising the CD7 targeting moiety. Lastly, methods of treatment of a CD7-positive cancer, preferably T-ALL are also provided.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 40/42 - Cancer antigens

Goods & Services

Incubators [medical devices], incubators for newborns.

Abstract

The present disclosure relates to a computer implemented method, system, and computer program for in silico surgical planification of a left atrial appendage occlusion (LAAO), wherein the risk of developing a device-associated thrombosis prior to a LAAO surgical intervention is evaluated. The positioning of the 3D model of the left atrial appendage occluder is determined according to anatomical characteristics of the left atrium of the patient, a first compression value and a structural simulation that provides a second compression value. The method further computes a risk score for device-induced thrombosis by analysing computational fluid dynamics calculations in conjunction with patient's medical parameters. This risk assessment aids in optimizing the positioning of the LAAO device, potentially reducing the incidence of post-operation thrombosis.

IPC Classes  ?

• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

It relates to Elvitegravir or a pharmaceutically acceptable salt thereof for use in the treatment of a bacterial infection caused by multidrug-resistant Gram-positive bacteria.

IPC Classes  ?

• A61K 31/47 - QuinolinesIsoquinolines
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/04 - Antibacterial agents

Abstract

The present invention provides methods for obtaining human induced pluripotent stem cells (hiPSC)-derived neuronal cells which are useful for the diagnosis of neurological disorders associated with the presence of neuronal antibodies. In particular, the invention provides a method for obtaining hiPSC-derived neuronal cells, wherein the method comprises culturing neuronal progenitor cells for at least three weeks in proneural medium in optimized conditions. The invention further covers the use of neuronal cells obtained by the method of the invention as a diagnostic test in neurological disorders associated with the presence of neuronal antibodies and kits comprising the same.

IPC Classes  ?

• C12N 5/0793 - Neurons

Abstract

An instrument for transorbital endoscopic surgery is proposed. The instrument comprises a handle; a support element, the handle being movably attached, at one end, to the support element; a first arm and a second arm, each one comprising a fixing portion, which connects the arm to the support element, and an anchoring portion, which is releasably attached to the fixing portion, one of the anchoring portions being configured to be anchored to a first fissure of the orbital cavity and the other one of the anchoring portions being configured to be anchored to a second fissure of the orbital cavity, each one of the anchoring portions comprising a given curvature; a mesh, arranged between and connected to each one of the anchoring portions to gather the periorbital when the anchoring portions are anchored to the first and seconds fissures; and sensors to detect an applied pressure applied to the first and second fissures.

IPC Classes  ?

• A61B 17/02 - Surgical instruments, devices or methods for holding wounds open, e.g. retractorsTractors
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

Non-invasive biomarkers for the diagnosis and prognosis of portal hypertension. Advantageously, the markers allow to appropriately differentiate between the non-clinical and clinically significant portal hypertension, thus being possible a more precise management of the therapeutic protocols.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

The present invention provides new therapeutic approaches for the treatment or prevention of FGFR4-expressing cancers, including those resistant to other therapies.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention refers to a CD19-specific chimeric antigen receptor (CAR) T-cell therapy and to its use for treating CD19+ malignancies.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The present invention relates to liposomes that encapsulate uric acid, methods for its preparation and uses of said liposomes.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to gene therapy for the treatment of Glutaric Aciduria type I (GA-1), wherein the treatment comprises the administration of a nucleic acid comprising an expression cassette comprising the nucleotide sequence of a chimeric promoter and the nucleotide sequence encoding for the human glutaryl-CoA dehydrogenase enzyme (GCDH). Virions, cells and pharmaceutical composition comprising said nucleic acid are also provided.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

The present invention refers to the medical field. Particularly, the present invention refers to autologous/allogeneic CAR (chimeric antigen receptor)-T/NK cells for use in the treatment of invasive fungal infections.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61P 31/10 - Antimycotics
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

This application relates to steerable catheters comprising first and second steering sections that are respectively configured to steer in opposite directions within the same plane. The application also relates to a system comprising a steerable catheter as disclosed and a patch deployment device that is deployable via the catheter.

IPC Classes  ?

• A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
• A61F 2/95 - Instruments specially adapted for placement or removal of stents or stent-grafts

Abstract

The invention relates to the use of a MiRNA panel, preferably detected in plasma, as biomarkers for the diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) and/or the prognosis of pulmonary embolism (PE). The invention also relates to a method which uses level of expression of said miRNAs to determine the diagnosis of CTEPH and/or the prognosis of EP, as well as a kit for the detection of these biomarkers in biological samples.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to a CD229 and a BCMA targeting moiety, wherein the CD229 targeting moiety is an antibody, F(ab')2, Fab, scFab or scFv. The present invention further provides CARs, nucleic acid, cells, pharmaceutical compositions and kits comprising the CD229 and BCMA targeting moiety. Methods of treatment of a CD229-positive cancer, preferably Multiple Myeloma, are also provided.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A female urine collector (1), comprising a base (2) configured to attach to the vaginal area of a patient (P) around the urethral orifice; and a collection bag (3) attached to the base configured to collect urine from the patient. Said urine collector comprises adhesive means (4) that attach the base to the collecting bag, configured to allow the removal of the collecting bag while keeping the base adhered to the patient.

IPC Classes  ?

• A61F 5/443 - Devices worn by the patient for reception of urine, faeces, catamenial or other dischargeColostomy devices having hydrocolloid type seals, e.g. gels, starches, karaya gums
• A61F 5/455 - Genital receptacles for collecting urine or discharge from female member

Goods & Services

Incubation units.

Goods & Services

Incubation units.

Abstract

The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition. The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition. The invention also provides processes for its preparation as well as it use in therapy. The live-cell based composition of the invention is stable at mild conditions.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate

Abstract

The present invention refers to an in vitro method for the prognosis of patients suffering from HER2+ breast cancer and/or for the prediction of response to anti-HER2 therapies in patients suffering from HER2+ breast cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6844 - Nucleic acid amplification reactions

Abstract

The present invention relates to cyclic peptides of a particular formula (I), X1X2X3X4CX6X7X8PX10X11X12X13CX15X16X17P (SEQ ID NO: 1) (I), fwherein X1 to X17 take several meanings, and X1 and D-Pro at position 18 are linked by a peptide bond; which cyclic peptides are useful as antimicrobial agents. The invention also relates to particular bicyclic compounds, in which cysteines at positions 5 and 14 are crosslinked by a disulfide bond. The invention also relates to pharmaceutical compositions comprising the said peptides and to the medical applications of the peptides or of the compositions comprising them.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 7/64 - Cyclic peptides containing only normal peptide links
• A61P 31/04 - Antibacterial agents
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

in vitro in vitro use of DNA copy number alterations (CNAs) for predicting the response of patients with HR+/HER2− breast cancer to a treatment comprising targeted therapy, such as CDK4/6 inhibitors, and/or endocrine therapy; for the prognosis of patients with HR+/HER2− breast cancer; for monitoring patients with HR+/HER2− breast cancer; or for classifying patients with HR+/HER2− breast cancer into responder or non-responder to a treatment comprising targeted therapy, such as CDK4/6 inhibitors, and/or endocrine therapy.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A method and a system for determining the amount of oxygen required by a user with respiratory problems are disclosed. First data about several users with respiratory problems is stored in a database. The method a) collects second data from a monitored user while (s)he is performing a test at a first location; b) computes a user’s behavioral model executing a first algorithm on the first and second data; c) collects, every period of time t1, third data of the user while (s)he is performing an activity at a second location; d) adjusts, every period of time t2, the computed user’s behavioral model using the first algorithm, providing a customized user’s behavioral model as a result; and e) computes an estimator of the quantity of oxygen to be delivered to the user by executing a second algorithm on the customized user’s behavioral model.

IPC Classes  ?

• A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
• G06N 20/00 - Machine learning

Abstract

The present invention refers to an in vitro method for the prognosis of patients suffering from HER2+ breast cancer, for the prediction of response to anti-HER2 therapies and/or for predicting survival benefit from anti-HER2 therapies.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to liposomes that encapsulate uric acid, methods for its preparation and uses of said liposomes.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

The present invention relates to a bispecific antibody comprising an anti-CD19 single-chain fragment variable and an anti-CD3 single-chain fragment variable. The present invention also relates to T cells secreting the bispecific antibody, method of preparation of T cells secreting the bispecific antibody and uses thereof in the treatment of a hematological malignancy selected from the group consisting of lymphoma, leukemia and myeloma.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The present invention provides a method for deciding a check-point inhibitor (ICI)-based therapy, for a patient suffering from cancer, the method comprising the steps: a) measuring the expression level of the following markers: TGFB1, ZEB1, FAP, ZEB2, GLUL, ENTPD1, GOT1, LDHA, TWIST1, and GLS, in an isolated cancerous biological tissue sample from the patient; b) determining which markers are differentially expressed; and c) classifying the sample, depending on the markers differentially expressed, in one of the following clusters: cluster 1: when ZEB1, ZEB2, ENTPD1, FAP and GLUL are up-regulated; cluster 2: when GLS is upregulated; and LDHA, GOT1, ZEB1, ZEB2 and ENTPD1 are downregulated; and cluster 3: when GOT1 is upregulated and TGFB1 and TWIST 1 are downregulated.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present inventors provide non-invasive biomarkers for the diagnosis and prognosis of portal hypertension. Advantageously, the markers of the invention also allow to appropriately differentiate between the non-clinical and clinically significant portal hypertension, thus being possible a more precise management of the therapeutic protocols.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention refers to the medical field. Particularly, the present invention refers to autologous/allogeneic CAR (chimeric antigen receptor)-T/NK cells for use in the treatment of invasive fungal infections.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

The present invention refers to a CD19-specific chimeric antigen receptor (CAR) T-cell therapy and to its use for treating CD19+ malignancies.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

The present invention refers to a CD19-specific chimeric antigen receptor (CAR) T-cell therapy and to its use for treating CD19+ malignancies.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

The present invention provides a patch deployment device, the device comprising a pusher wire having a proximal end and a distal end; a plurality of deployment wires, wherein each deployment wire: has a first end and a second end, and the first end and the second end are connected to the distal end of the pusher wire; and is configured to be in an unexpanded state when positioned and constrained within a catheter, and configured to self-expand into an expanded state when positioned beyond a distal end of the catheter and not constrained, wherein in the expanded state at least a portion of the wire is positioned substantially within a plane that is substantially perpendicular to the longitudinal axis of the pusher wire and has an asymmetric form when viewed along a direction parallel to the longitudinal axis of the pusher wire.

IPC Classes  ?

• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
• A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents

Abstract

Non-invasive method for the diagnosis or screening of colorectal cancer and/or pre-cancerous stage thereof. The present invention refers to an in vitro method for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Patch (1) for sealing an amniotic membrane, wherein the patch (1) comprises a support (11) and an adhesive (12) that is activated in presence of amniotic liquid or a wet environment. Device for placing said patch (1) comprising a cannula (2) for inserting said patch (1) in a rolled-up position, said cannula (2) being provided with a handle (3); and a dipstick (4) provided with a pusher (5), said dipstick (4) being inserted inside the cannula (2) in the use position. The patch adheres efficiently on the amniotic membrane, adapts to the elastic properties of this membrane, and by attaching only to the amnion it does not interfere with the natural sliding movements of one membrane against each other, together with the device to ensure that the patch is placed in the proper position without damaging the membrane.

IPC Classes  ?

• A61B 17/00 - Surgical instruments, devices or methods

Abstract

The present invention provides therapeutics for the treatment of Multiple myeloma. In particular, the present invention provides chimeric antigen receptor (CAR) T-cells that can target the B cell maturation antigen.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors

Abstract

in vitro in vitro use of a Coronavirus antigen, measured in plasma, serum or blood samples obtained from the patient, for the prognosis and/or for predicting the mortality risk of patients suffering from Coronavirus infection, for predicting the response of patients suffering from Coronavirus infection to an antiviral therapy or for selecting patients suffering from Coronavirus infection for receiving an antiviral therapy.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition. The invention also provides processes for its preparation as well as it use in therapy. The live-cell based composition of the invention is stable at mild conditions.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate

Abstract

A method and a system for determining the amount of oxygen required by a user with respiratory problems are disclosed. First data about several users with respiratory problems is stored in a database. The method a) collects second data from a monitored user while (s)he is performing a test at a first location; b) computes a user's behavioral model executing a first algorithm on the first and second data; c) collects, every period of time t1, third data of the user while (s)he is performing an activity at a second location; d) adjusts, every period of time t2, the computed user's behavioral model using the first algorithm, providing a customized user's behavioral model as a result; and e) computes an estimator of the quantity of oxygen to be delivered to the user by executing a second algorithm on the customized user's behavioral model.

IPC Classes  ?

• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
• A61M 16/10 - Preparation of respiratory gases or vapours
• A61B 5/083 - Measuring rate of metabolism by using breath test, e.g. measuring rate of oxygen consumption
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61M 16/06 - Respiratory or anaesthetic masks
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters

Abstract

Methods and systems for enhancing glucose monitoring are disclosed that allow for more precise control of the glucose level by taking into account new control parameters. The disclosed methods include obtaining an initial CGM value (CGM) from a CGM sensor, obtaining a set of parameters from a wearable device, calculating an error (E) in the initial CGM value (CGM) using a regression algorithm based upon the initial CGM value and the obtained set of parameters, and calculating an enhanced CGM value (eCGM) according to the formula eCGM=CGM−E. The error (E) is calculated according to the formula: E=θ*p, wherein E is the calculated error, θ represents the data obtained from the wearable device after removing a baseline value of each wearable, and p represents regression parameters based upon an error value obtained in a training population.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/1495 - Calibrating or testing in vivo probes
• A61B 5/01 - Measuring temperature of body parts
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic

Abstract

in vitroin vitro method for the prognosis of patients suffering from HER2+ breast cancer and/or for the prediction of response to anti-HER2 therapies in patients suffering from HER2+ breast cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Goods & Services

Scientific, research, navigation, surveying, photographic, cinematographic, audiovisual, optical, weighing, measuring, signalling, detecting, testing, inspecting, life-saving and teaching apparatus and instruments; Apparatus, instruments and cables for electricity; Apparatus and instruments for transforming electricity; Apparatus and instruments for transforming electricity; Apparatus for measuring, monitoring and analyzing electricity consumption; Apparatus and instruments for recording, transmitting, reproducing or processing sound, images or data; Recorded or downloadable media; Data storage media; Data storage devices; Data storage programs; Software; Computer software, recorded; Downloadable software; Downloadable computer software for remote monitoring and analysis; Digital storage media; Magnetic data media; Optical data media; Computers and computer peripherals; Computer network-attached storage [NAS] hardware; Monitoring instruments; Application software. Surgical, medical, dental and veterinary apparatus and instruments; Orthopedic articles; Suture materials; Therapeutic and assistive devices adapted for the disabled; Medical apparatus and instruments; Diagnostic apparatus for medical purposes; Tools for medical diagnostics. Scientific and technological services, as well as related research and design services; industrial analysis, industrial research and industrial design services; Quality control and authentication; Design and development of hardware and software; Configuration of computer software; Installation of computer software; Updating, maintenance and repair of computer software; Software as a service [SaaS]; Platform as a service [PaaS]; Scientific research for medical purposes. Medical services; Animal healthcare services; Hygienic and beauty care for human beings or animals; Hospital services; Telemedicine services.

Goods & Services

Scientific, research, navigation, surveying, photographic, cinematographic, audiovisual, optical, weighing, measuring, signalling, detecting, testing, inspecting, life-saving and teaching apparatus and instruments; Apparatus, instruments and cables for electricity; Apparatus and instruments for transforming electricity; Apparatus and instruments for transforming electricity; Apparatus for measuring, monitoring and analyzing electricity consumption; Apparatus and instruments for recording, transmitting, reproducing or processing sound, images or data; Recorded or downloadable media; Data storage media; Data storage devices; Data storage programs; Software; Computer software, recorded; Downloadable software; Downloadable computer software for remote monitoring and analysis; Digital storage media; Magnetic data media; Optical data media; Computers and computer peripherals; Computer network-attached storage [NAS] hardware; Monitoring instruments; Application software. Surgical, medical, dental and veterinary apparatus and instruments; Orthopedic articles; Suture materials; Therapeutic and assistive devices adapted for the disabled; Medical apparatus and instruments; Diagnostic apparatus for medical purposes; Tools for medical diagnostics. Scientific and technological services, as well as related research and design services; industrial analysis, industrial research and industrial design services; Quality control and authentication; Design and development of hardware and software; Configuration of computer software; Installation of computer software; Updating, maintenance and repair of computer software; Software as a service [SaaS]; Platform as a service [PaaS]; Scientific research for medical purposes. Medical services; Animal healthcare services; Hygienic and beauty care for human beings or animals; Hospital services, Telemedicine services.

Abstract

PIKC3APIKC3A gene.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to a bispecific antibody comprising an anti-CD19 single- chain fragment variable and an anti-CD3 single-chain fragment variable. The present invention also relates to T cells secreting the bispecific antibody, method of preparation of T cells secreting the bispecific antibody and uses thereof in the treatment of a hematological malignancy selected from the group consisting of lymphoma, leukemia and myeloma.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The present invention provides a patch deployment device, the device comprising a pusher wire having a proximal end and a distal end; a plurality of deployment wires, wherein each deployment wire: has a first end and a second end, and the first end and the second end are connected to the distal end of the pusher wire; and is configured to be in an unexpanded state when positioned and constrained within a catheter, and configured to self-expand into an expanded state when positioned beyond a distal end of the catheter and not constrained, wherein in the expanded state at least a portion of the wire is positioned substantially within a plane that is substantially perpendicular to the longitudinal axis of the pusher wire and has an asymmetric form when viewed along a direction parallel to the longitudinal axis of the pusher wire.

IPC Classes  ?

• A61B 17/00 - Surgical instruments, devices or methods

Goods & Services

Downloadable computer applications for sanitary services. Telemedicine services.

Abstract

The present invention provides therapeutics for the treatment of Multiple myeloma. In particular, the present invention provides chimeric antigen receptor (CAR) T-cells that can target the B cell maturation antigen.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Non-invasive method for the diagnosis or screening of colorectal cancer and/or pre-cancerous stage thereof. The present invention refers to an in vitro method for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Patch (1) for sealing an amniotic membrane, wherein the patch (1) comprises a support (11) and an adhesive (12) that is activated in presence of amniotic liquid or a wet environment. Device for placing said patch (1) comprising a cannula (2) for inserting said patch (1) in a rolled-up position, said cannula (2) being provided with a handle (3); and a dipstick (4) provided with a pusher (5), said dipstick (4) being inserted inside the cannula (2) in the use position. The patch adheres efficiently on the amniotic membrane, adapts to the elastic properties of this membrane, and by attaching only to the amnion it does not interfere with the natural sliding movements of one membrane against each other, together with the device to ensure that the patch is placed in the proper position without damaging the membrane.

IPC Classes  ?

• A61B 17/00 - Surgical instruments, devices or methods
• A61B 17/42 - Gynaecological or obstetrical instruments or methods

Abstract

The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition. The invention also provides processes for its preparation as well as it use in therapy. The live-cell based composition of the invention is stable at mild conditions.

IPC Classes  ?

• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 35/74 - Bacteria
• A61K 35/741 - Probiotics

Abstract

The invention relates to a method, intended to be implemented using a computer system by means of management software, which consists in establishing differentiated groups of input variables in a specific manner and combining them according to valuation rules based on concretion algorithms, which establish the calculation thereof in the progression of tumour biomarker readings at different concentrations as diagnostic elements of neoplasia, together with other elements, for high specificity, varying by tumour type, history and stage. The obtained results, varying according to the tumour and the biomarkers, oscillate between sensitivities of more than 65% in stage I and II tumours, 75% in locally advanced neoplasms and 80-95% in metastasic neoplasms.

IPC Classes  ?

• G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics

Abstract

The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• G16B 25/00 - ICT specially adapted for hybridisationICT specially adapted for gene or protein expression
• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Present invention discloses in vitroPresent invention discloses in vitro method for the diagnosis of multiple system atrophy comprising determining, in an isolated cerebrospinal fluid sample of a subject, the level of expression of one or more cytokines. It also relates to particular combinations of the levels of these cytokines that provide information for the differential diagnosis of multiple system atrophy and Parkinson's disease.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

T. cruziT. cruziT. cruzi parasite protein including pyruvate phosphate dikinase, such that the detected protein expression product can serve as potential biomarker in the context of the therapeutic response and prognosis of the disease during chronic infection.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention refers to a composition comprising uric acid for its use in the treatment of brain stroke in a patient treated by means of mechanical thrombectomy.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 38/49 - UrokinaseTissue plasminogen activator

Abstract

The present invention refers to an in vitro method for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer comprising the detection and/or quantification of the expression of HER2 in an isolated biological sample of the patient, either (1) before or (2) before and during the anti-HER2 therapy in the absence of chemotherapy treatment. The present invention also refers to the use of a gene expression product of HER2 as a as an in vitro marker for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer, or alternatively as an in vitro marker for deciding or recommending whether to initiate an alternative medical regime to anti-HER2 therapy without chemotherapy in a patient with HER2+ breast cancer.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention refers to an in vitro method for screening for subjects at risk of developing pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas (IPMN) comprising: (a) measuring the expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hsa-miR-1304, or of at least hsa-miR-151b, or of at least hsa-miR-3120-3p, or of at least hsa-miR-3133, or of at least hsa-miR-3714, or of at least hsa-miR-4468, or of at least hsa-miR-4639-5p, or of at least hsa-miR-4713-5p, or of at least hsa-miR-4714-5p, or of at least hsa-miR-4770, or of at least hsa-miR-548d-3p, or of at least hsa-miR-761, obtained from an isolated biological sample of the subjects to be screened; and (b) comparing said expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hsa-miR-1304, or of at least hsa-miR-151b, or of at least hsa-miR-3120-3p, or of at least hsa-miR-3133, or of at least hsa-miR-3714, or of at least hsa-miR-4468, or of at least hsa-miR-4639-5p, or of at least hsa-miR-4713-5p, or of at least hsa-miR-4714-5p, or of at least hsa-miR-4770, or of at least hsa-miR-548d-3p, or of at least hsa-miR-761, of the subjects to be screened with an already established expression pattern or level, wherein over expression of at least any of the above mentioned miRNAs is indicative of pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas (IPMN).

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips

Abstract

The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates in general to the field of colorectal cancer detection, and more particularly, to plasma microRNAs for the detection of early colorectal cancer. Specifically, the present invention includes methods, kits and biomarkers for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: A method for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: obtaining one or more biological samples from the subject suspected of suffering from colorectal neoplasia; measuring an overall expression pattern or level of one or more microRNAs obtained from the one or more biological samples of the subject; and comparing the overall expression pattern of the one or more microRNAs from the biological sample of the subject suspected of suffering from colorectal neoplasia with the overall expression pattern of the one or more microRNAs from a biological sample of a normal subject, wherein the normal subject is a healthy subject not suffering from colorectal neoplasia, wherein overexpression of a combination of miR19a and miR19b, or miR19a and miR19b and miR15b is indicative of colorectal cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection

Abstract

The present invention relates in general to the field of colorectal cancer detection, and more particularly, to plasma microRNAs for the detection of early colorectal cancer. Specifically, the present invention includes methods, kits and biomarkers for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: A method for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: obtaining one or more biological samples from the subject suspected of suffering from colorectal neoplasia; measuring an overall expression pattern or level of one or more microRNAs obtained from the one or more biological samples of the subject; and comparing the overall expression pattern of the one or more microRNAs from the biological sample of the subject suspected of suffering from colorectal neoplasia with the overall expression pattern of the one or more microRNAs from a biological sample of a normal subject, wherein the normal subject is a healthy subject not suffering from colorectal neoplasia, wherein overexpression of a combination of miR19a and miR19b, or miR19a and miR19b and miR15b is indicative of colorectal cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection

Abstract

The present invention relates to a composition comprising uric acid for use in the treatment of brain stroke patients treated by means of mechanical thrombectomy.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention is based on the discovery of genetic polymorphisms that are associated with early onset of L-DOPA-induced dyskinesia (LID) and the severity of LID in patients affected of Parkinson disease (PD). In particular, the present invention relates to predictive medicine methods based on the determination of certain genetic polymorphisms, as well as kits for carrying out said methods.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The invention relates to methods for predicting the onset of extrapyramidal symptoms (EPS) induced by an antipsychotic-based treatment as well as methods for providing personalized medicine to patients based on the sequence of several SNPs associated with the onset of EPS. The invention relates as well to kits for carrying out the diagnostic and predictive medicine methods.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention refers to an in vitro method for determining the efficacy of anti- HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer comprising the detection and/or quantification of the expression of HER2 in an isolated biological sample of the patient, either (1) before or (2) before and during the anti-HER2 therapy in the absence of chemotherapy treatment. The present invention also refers to the use of a gene expression product of HER2 as a as an in vitro marker for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer, or alternatively as an in vitro marker for deciding or recommending whether to initiate an alternative medical regime to anti-HER2 therapy without chemotherapy in a patient with HER2+ breast cancer.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to the field of medicine and provides compositions and kits-of-parts comprising a CD6 product and Imipenem, in particular for their use in a therapeutic and/or preventive method of treatment, in a mammal including a human, of an infectious disease, or of an inflammatory condition related to an infectious disease, or of an inflammatory disease related to the presence of a product derived from an infectious agent.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Abstract

A computer implemented method to identify the ventricular arrhythmogenic substrate in myocardial scar or fibrotic tissue and computer program products A plurality of mapping points acquired from a patient are stored in a signal acquisition unit, said mapping points including a ECG signals, EGM signals and a 3D location of the EGM signals, the method comprising for a reference mapping point: a) detecting each beat present in one recorded ECG signal and identifying a beat of interest from the detected beats; b) identifying a principal EGM wave related to the identified beat of interest; c) identifying an onset and an end time landmarks of said principal EGM wave providing a primary delineated EGM signal and measuring a voltage amplitude of the primary delineated EGM signal; d) performing a further analysis of the primary delineated EGM; and e) creating a conducting channel map and a propagation map of the heart based on the result of a tagging performed during said analysis.

IPC Classes  ?

• A61B 5/04 - Measuring bioelectric signals of the body or parts thereof
• A61B 5/0452 - Detecting specific parameters of the electrocardiograph cycle
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/0408 - Electrodes specially adapted therefor
• A61B 5/042 - Electrodes specially adapted therefor for introducing into the body

Abstract

The present invention refers to an in vitro method for screening for subjects at risk of developing pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas (IPMN) comprising: (a) measuring the expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hsa-miR-1304, or of at least hsa-miR-151b, or of at least hsa-miR-3120-3p, or of at least hsa-miR-3133, or of at least hsa-miR-3714, or of at least hsa-miR-4468, or of at least hsa-miR-4639-5p, or of at least hsa-miR-4713-5p, or of at least hsa-miR-4714-5p, or of at least hsa-miR-4770, or of at least hsa-miR-548d-3p, or of at least hsa-miR-761, obtained from an isolated biological sample of the subjects to be screened; and (b) comparing said expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hsa-miR-1304, or of at least hsa-miR-151b, or of at least hsa-miR-3120-3p, or of at least hsa-miR-3133, or of at least hsa-miR-3714, or of at least hsa-miR-4468, or of at least hsa-miR-4639-5p, or of at least hsa-miR-4713-5p, or of at least hsa-miR-4714-5p, or of at least hsa-miR-4770, or of at least hsa-miR-548d-3p, or of at least hsa- miR-761, of the subjects to be screened with an already established expression pattern or level, wherein over expression of at least any of the above mentioned miRNAsis indicative of pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas (IPMN).

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention relates to cerium oxide nanoparticles useful in the treatment of hepatocellular carcinoma (HCC), said nanoparticles being cerium oxide single-crystalline nanoparticles of formula (I) NP-(A)n (I), wherein NP is a single-crystalline cerium oxide nanoparticle with a crystal diameter from 3 to 24 nm; A is a molecule selected from the group consisting of albumin, polyvinylpyrrolidone, and combinations thereof; and n is an integer from 0 to 40, and wherein if the crystal diameter of the nanoparticle is from 3 to 7 nm, then n is an integer from 1 to 12. The invention proposes also particular nanoparticles of formula (I) as conjugates, as well as pharmaceutical compositions comprising them.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/51 - Nanocapsules
• A61K 33/24 - Heavy metalsCompounds thereof
• A61P 35/00 - Antineoplastic agents
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• C01F 17/00 - Compounds of rare earth metals

Abstract

The system comprising an internal unit (10) comprising two arrays of N transmitter and N receiver antennas (11R, 11T) for transmitting a microwave signal(s) to one or more body tissues of a patient and for detecting a scattered microwave signal(s) by said one or more body tissues; feeding and multiplexing means (12) in connection with said N transmitter and N receiver antennas (11T, 11R) and with an external computing unit (20) configured to receive said scattered microwave signal(s) and convert it/them into an image, wherein the feeding and multiplexing means (12) provide, under the control of a controller (21) of the external computing unit (20), a continuous sequential selection of different pairs of transmitter and receiver antennas (11T, 11R) to perform the transmission of the microwave signal(s) and the detection of the scattered microwave signal(s).

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The invention relates to the use of extracellular mitochondrial DNA as a quantitative biomarker for the sub-classification of patients suffering from Parkinson disease in the subgroups of familial or idiopathic Parkinson. The invention also relates to a method and to a kit for the sub-classification of patients suffering from Parkinson disease using said biomarker.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

A bioreactor for cell co-culture having at least first and second cell culture chambers which are separated by a porous membrane. The membrane has at least one sealing gasket integrated in the membrane and being integral therewith. The sealing gasket defines a closed perimeter delimiting a first cell culture area.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave

Abstract

The present invention provides methods for diagnosing psoriatic arthritis (PsA) in an individual. Specifically, the method relates to detecting the presence or absence of an intergenic deletion between the human ADAMTS9 and MAGI1 genes. Also provided herein are methods for determining whether a subject has a risk of developing PsA. The methods described herein can be used for selecting a treatment of a subject suspected of having PsA.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G16B 25/00 - ICT specially adapted for hybridisationICT specially adapted for gene or protein expression
• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The invention relates to a method for the prognosis of hepatocellular carcinoma in an isolated sample of a subject, the method comprising providing a DNA methylation signature, said signature obtained from the qualitative and quantitative methylation analysis of 36 selected CpG sites. The invention also disclosesparticular methods in which a Mortality Index score is provided from said signature.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Means and methods for measuring pain and adapted for calculating the level of nociception during general anesthesia or sedation from data including electroencephalogram (EEG), facial electromyogram (EMG), heart rate variability (HRV) by electrocardiogram (ECG) and plethysmography by impedance cardiography (ICG). In a preferred embodiment of this invention the parameters derived from the EEG, the HRV, the plethysmographic curve and the analgetics concentrations are either combined into one index on a scale from 0 to 100, where a high number is associated with high probability of response to noxious stimuli, while a decreasing index is associated with decreasing probability of response to noxious stimuli. Zero (0) indicates extremely low probability of response to noxious stimuli. In an alternative embodiment, only features from the EEG and ECG will be used or only features from EEG, ECG and ICG, to define the final index.

IPC Classes  ?

• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
• A61B 5/0402 - Electrocardiography, i.e. ECG
• A61B 5/0476 - Electroencephalography
• A61B 5/0488 - Electromyography

Abstract

Peptides against the external protein A (OmpA) are provided for the treatment of infections caused by Gram negative pathogens, especially Acinetobacter baumanii, Escherichia coli or Pseudomonas aeruginosa. Preferred cyclic hexapeptides comprise tryptophan, proline and arginine,and a preferred cyclic hexapeptide has the sequence c- (WPRWPR). Variants thereof with modified amino acids, D-amino acids or different order of the amino acids in the cyclic hexapeptide are also disclosed.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/50 - Cyclic peptides containing at least one abnormal peptide link
• C07K 14/21 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Pseudomonadaceae (F)
• C07K 14/245 - Escherichia (G)
• A61K 38/12 - Cyclic peptides
• A61P 31/04 - Antibacterial agents

Abstract

The present invention provides methods for selecting an individual with psoriasis (Ps) or psoriatic arthritis (PsA) who should receive or who is likely to respond to a treatment with an anti-tumor necrosis factor alpha (anti-TNFα) therapy. In addition, provided herein are methods for selecting an individual with Ps or PsA who should receive or who is likely to respond to a therapy that is not an anti-TNFα therapy, e.g., a non-anti-TNFα therapy for the treatment of Ps or PsA. Specifically, the methods of the present invention relate to detecting the presence of distinct alleles of the PDE3A-SLCO1C1 locus which are associated with a clinical response to an anti-TNFα therapy or a non-anti-TNF therapy in patients with Ps or PsA.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention provides methods for predicting response to anti-TNFα biological agent treatment in a rheumatoid arthritis patient and methods for selecting a treatment for a rheumatoid arthritis patient, the methods comprising determining the level of expression of PIK3CD as a biomarker, and optionally also determining the level of expression of CX3CL1 as a second biomarker. The invention additionally provides kits for carrying out the methods described.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The invention relates to the use of selective agonists of beta-3 adrenergic receptors for the treatment and/or prevention of pulmonary hypertension.

IPC Classes  ?

• A61K 31/426 - 1,3-Thiazoles
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
• A61K 31/63 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide

Abstract

c) automatically identifying the possible channels by means of automatically obtaining candidate channels regions (CCR), dilating the perimeters of the well-defined zone (S) patches. The method includes embodiments for a layered approach, an EAM polygonal mesh approach and a volume approach. The computer program product is adapted to implement part or all of the steps of the method of the invention. The EAM system comprises computing navigation means implementing the method of the invention.

IPC Classes  ?

• G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
• G06T 7/00 - Image analysis
• G06T 7/11 - Region-based segmentation
• G06T 7/187 - SegmentationEdge detection involving region growingSegmentationEdge detection involving region mergingSegmentationEdge detection involving connected component labelling

Abstract

The invention relates to methods for predicting the onset of extrapyramidal symptoms (EPS) induced by an antipsychotic-based treatment as well as methods for providing personalized medicine to patients based on the sequence of several SNPs associated with the onset of EPS. The invention relates as well to kits for carrying out the diagnostic and predictive medicine methods.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The method comprises identifying, in a 3D volume, a zone of a first type (H), a zone of a second type (BZ) and a zone of a third type (C) and: - automatically identifying as a candidate channel (bz) a path running through the zone of a second type (BZ) and extending between two points of the zone of a first type (H); and - automatically performing, on a topological space (H_and_BZ_topo), homotopic operations between the candidate channel (bz) and paths (h) running only through the zone of a first type (H), and if the result of said homotopic operations is that the candidate channel (bz) is not homotopic to any path running only through the zone of a first type (H) identifying the candidate channel (bz) as a constrained channel. The computer program product implements the steps of the method of the invention.

IPC Classes  ?

• G06T 7/00 - Image analysis

Abstract

A bioreactor (1) for cell co-culture comprising at least first and second cell culture chambers (2, 4). The first and second chambers (2, 4) are separated by a porous membrane (6) for cell culture. The membrane (6) comprises at least one sealing gasket (12) integrated in the membrane (6) being integral therewith. The sealing gasket (12) defines a closed perimeter delimiting a first cell culture area (16).

IPC Classes  ?

• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave

Abstract

A bioreactor (1) for cell co-culture comprising at least first and second cell culture chambers (2, 4). The first and second chambers (2, 4) are separated by a porous membrane (6) for cell culture. The membrane (6) comprises at least one sealing gasket (12) integrated in the membrane (6) being integral therewith. The sealing gasket (12) defines a closed perimeter delimiting a first cell culture area (16).

IPC Classes  ?

• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave

Abstract

A needle guiding device for ultrasound guided puncture and corresponding kit. The device comprises coupling means (2) for the ultrasound transducer (100) and which have an examination end (24) and an insertion end (26) of the transducer (100). The longitudinal section of the coupling means (2) defines a main plane (12) of the device. The device (1) comprises a needle (104) support (4) having a guiding opening (6) for the needle (104). The guiding opening (6) tapers progressively such that the needle (104) is guided being able to freely rock on said second end (10), close to the main plane (12) at least in a plane forming an acute angle (α) relative to the main plane (12) and intersecting it downstream of the end (10). The invention also proposes a kit for ultrasound guided puncture containing an ultrasound gel.

IPC Classes  ?

• A61B 17/34 - TrocarsPuncturing needles
• A61B 19/02 - Protective casings or covers for appliances or instruments, e.g. boxes or sterile covers; Instrument tables or cupboards; Doctors' bags

Abstract

The present invention concerns subject matter connected to or making use of lgLON5, lgLON5 fragments and variants of lgLON5 and lgLON5-fragments. In particular the present invention relates to a use of a polypeptide comprising one or more sequences of IgLON5, an lgLON5-fragment or a variant thereof for the diagnosis of a disease, in vitro methods for diagnosing such a disease, a polypeptide comprising one or more sequences of lgLON5, an lgLON5-fragment or a variant thereof or a nucleic acid encoding said polypeptide for use in the treatment of a disease, a pharmaceutical composition comprising such polypeptide, a method for treating such a disease, an autoantibody binding to IgLON5, an lgLON5-fragment or a variant thereof, a method for isolating such autoantibody, a medical or diagnostic device comprising such autoantibody or such polypeptide and a test kit for the diagnosis of a disease, which test kit comprises such autoantibody and/or such polypeptide.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease

Abstract

The invention relates to a method with biofeedback for training muscles of the pelvic floor, applicable to the treatment of urinary incontinence, fecal incontinence and prolapse of pelvic organs, using a portable electronic device for capturing, by means of sensors, EMG signals relating to abdominal activity and the area to be treated during muscle exercises, said device providing results visually and/or acoustically, the method comprising: placing a vaginal or rectal sensor (10) and two sensors (11) in the lower abdominal area, performing exercises working the muscles of the pelvic floor, providing evaluation of the exercises performed and storing results. The user places the sensors herself, the device evaluating the correct placement of the sensors indicating to the user that the suitable position has been reached through said acoustic and/or visual means, and performing a step prior to the exercises for acquiring muscle tone.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/0488 - Electromyography
• A63B 23/20 - Exercising apparatus specially adapted for particular parts of the body for vaginal muscles
• A63B 71/06 - Indicating or scoring devices for games or players
• A61B 5/20 - Measuring urological functions
• A61B 5/04 - Measuring bioelectric signals of the body or parts thereof
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb

Abstract

The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to synergistic combinations, including immunoconjugates, of an anti-IgE antibody, such as omalizumab, with an EP2 receptor agonist and their use in the prevention or treatment of an IgE-mediated disorder, preferably asthma.

IPC Classes  ?

• C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
• A61K 31/557 - Eicosanoids, e.g. leukotrienes

Abstract

The present invention is related to 4-amino-6-(2,6-dichlorophenyl)-2- (phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, to the preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in the treatment and/or prevention of a non-Hodgkin's lymphoma.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents